Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30962862 | 1.00 | PNMT (0.46) | PNMTGABRA1GABRB2TAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11833876 | 0.98 | PNMT (0.45) | PNMTGABRA1GABRB2TAAR1ALDH1A1 | |
| SCHEMBL1332031 | 0.83 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1GAA | |
| SCHEMBL262868 | 0.83 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1GAA | |
| SCHEMBL3786637 | 0.83 | TAAR1 (0.44) | PNMTTAAR1ALDH1A1IDO1MEN1 | |
| SCHEMBL7795555 | 0.82 | PNMT (0.38) | PNMTGABRA1GABRB2TAAR1IDO1 | |
| SCHEMBL3675893 | 0.81 | PNMT (0.50) | PNMTTAAR1ALDH1A1IDO1 | |
| SCHEMBL30303201 | 0.81 | GABRA1 (0.48) | PNMTGABRA1GABRB2ALDH1A1CSNK2A2 | |
| Methylene Chloride SCHEMBL27741172 | 0.81 | GABRA1 (0.48) | PNMTGABRA1GABRB2ALDH1A1CSNK2A2 | |
| Hydrochloric Acid SCHEMBL625383 | 0.80 | GABRA1 (0.52) | GABRA1GABRB2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0171588-A1 | Chain-lengthening or cross-linking agent | LONZA AG (CH) | 1986-02-19 | — | — | EP | claimed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-4978791-A | CROSSLINKING OR CHAIN EXTENSION AGENTS FOR POLYURETHANES OR EPOXY RESINS | LONZA LTD. (CH) | 1990-12-18 | — | — | US | disclosed |
| EP-0171588-B1 | CHAIN-LENGTHENING OR CROSS-LINKING AGENT | LONZA AG (CH) | 1990-09-26 | — | — | EP | disclosed |
| EP-0171588-A1 | Chain-lengthening or cross-linking agent | LONZA AG (CH) | 1986-02-19 | — | — | EP | disclosed |
| US-4418209-A | ANTIULCER, ANTIARRYTHMIC, ANTIDIARRHEAL, ANTISPASMODIC, ANTIPARASITIC, AND ANTISECRETORY AGENTS | WILLIAM H. RORER, INC. (US) | 1983-11-29 | — | — | US | disclosed |
| US-4326075-A | ANTIDIARRHEA AGENTS | WILLIAM H. RORER, INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4203920-A | ANTIDIARRHEAL | WILLIAM H. RORER, INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4178387-A | ADMINISTERING AMIDINOUREAS | WILLIAM H. RORER, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-3959488-A | 1-Substituted biguanides for treating hyperacidity or ulceration | WILLIAM H. RORER, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | PNMT 4648/4885GABRA1 3604/4885GABRB2 3264/4885 |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | PNMT 4879/4885GABRA1 2922/4885GABRB2 2882/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | PNMT 4879/4885GABRA1 2922/4885GABRB2 2882/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | PNMT 1048/4885GABRA1 1989/4885GABRB2 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.